These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 28411174)

  • 21. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
    Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
    Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T; Sullivan HC; Hendrickson JE
    J Clin Apher; 2024 Jun; 39(3):e22127. PubMed ID: 38803152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.
    Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H
    Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
    Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
    Holmberg LA; Linenberger M; Connelly-Smith L
    Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
    Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
    Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
    Matsue K; Kumagai K; Sugiura I; Ishikawa T; Igarashi T; Sato T; Uchiyama M; Miyamoto T; Ono T; Ueda Y; Kiguchi T; Sunaga Y; Sasaki T; Suzuki K
    Int J Hematol; 2018 Nov; 108(5):524-534. PubMed ID: 30043330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.
    Avramova BE; Yordanova MN; Konstantinov DN; Bobev DG
    Drug Des Devel Ther; 2011; 5():407-9. PubMed ID: 21966213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor.
    Zucenka A; Peceliunas V; Maciutaite E; Chaleckaite J; Jakimaviciute R; Griskevicius L
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1304-1311. PubMed ID: 30871977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.
    Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Acta Haematol; 2016; 135(1):29-36. PubMed ID: 26303343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
    Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
    Cheng J; Schmitt M; Wuchter P; Buss EC; Witzens-Harig M; Neben K; Hundemer M; Hillengass J; Alexi R; Goldschmidt H; Chen BA; Ho AD; Schmitt A
    Transfusion; 2015 Feb; 55(2):275-83. PubMed ID: 25117969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.